[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PT1390074T - Novas composições e suas utilizações - Google Patents

Novas composições e suas utilizações

Info

Publication number
PT1390074T
PT1390074T PT2717851T PT02717851T PT1390074T PT 1390074 T PT1390074 T PT 1390074T PT 2717851 T PT2717851 T PT 2717851T PT 02717851 T PT02717851 T PT 02717851T PT 1390074 T PT1390074 T PT 1390074T
Authority
PT
Portugal
Prior art keywords
novel compositions
uses therefor
therefor
compositions
novel
Prior art date
Application number
PT2717851T
Other languages
English (en)
Inventor
Hector Frazer Ian
Original Assignee
Admedus Vaccines Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Admedus Vaccines Pty Ltd filed Critical Admedus Vaccines Pty Ltd
Publication of PT1390074T publication Critical patent/PT1390074T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
PT2717851T 2001-04-18 2002-04-18 Novas composições e suas utilizações PT1390074T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPR4468A AUPR446801A0 (en) 2001-04-18 2001-04-18 Novel compositions and uses therefor

Publications (1)

Publication Number Publication Date
PT1390074T true PT1390074T (pt) 2017-07-31

Family

ID=3828464

Family Applications (1)

Application Number Title Priority Date Filing Date
PT2717851T PT1390074T (pt) 2001-04-18 2002-04-18 Novas composições e suas utilizações

Country Status (8)

Country Link
US (2) US8858951B2 (pt)
EP (1) EP1390074B1 (pt)
AU (2) AUPR446801A0 (pt)
CA (1) CA2444048C (pt)
DK (1) DK1390074T3 (pt)
ES (1) ES2634256T3 (pt)
PT (1) PT1390074T (pt)
WO (1) WO2002083181A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818222B1 (en) * 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
EP1800697B1 (de) * 2001-06-05 2010-04-14 CureVac GmbH Stabilisierte mRNA mit erhöhtem G/C-Gehalt für die Gentherapie
US20050013826A1 (en) * 2002-12-20 2005-01-20 Shneider Alexander M. Vaccine compositions and methods
US9018012B2 (en) * 2005-01-20 2015-04-28 Nature Technology Corporation Vectors and methods for genetic immunization
GB2452958A (en) * 2007-09-20 2009-03-25 Glaxosmithkline Biolog Sa HIV vaccine compositions
MA41644A (fr) * 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
EP3548623A4 (en) 2016-11-30 2020-11-25 Advaxis, Inc. IMMUNOGENIC COMPOSITIONS TARGETING RECURRENT CANCER MUTATIONS AND THEIR USE PROCEDURES
CN111330002B (zh) * 2020-03-09 2020-12-01 北京鼎成肽源生物技术有限公司 靶向冠状病毒的通用dc细胞疫苗及其制备方法和应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4184917A (en) 1974-04-01 1980-01-22 Sandoz Ltd. Process for producing a structurally modified interferon
US4321365A (en) 1977-10-19 1982-03-23 Research Corporation Oligonucleotides useful as adaptors in DNA cloning, adapted DNA molecules, and methods of preparing adaptors and adapted molecules
US4293652A (en) 1979-05-25 1981-10-06 Cetus Corporation Method for synthesizing DNA sequentially
US4351901A (en) 1980-03-24 1982-09-28 Cetus Corporation Method for single nucleotide alteration
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US5196321A (en) 1986-10-02 1993-03-23 Massachusetts Institute Of Technology Methods for in vitro cleavage of ubiquitin fusion proteins
US5093242A (en) 1986-10-02 1992-03-03 Massachusetts Institute Of Technology Methods of generating desired amino-terminal residues in proteins
US5241078A (en) 1988-06-14 1993-08-31 Cetus Oncology Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5122463A (en) 1990-05-17 1992-06-16 Massachusetts Institute Of Technology Methods for trans-destabilization of specific proteins in vivo and dna molecules useful therefor
ATE234925T1 (de) * 1991-07-19 2003-04-15 Univ Queensland Impfstoffe gegen papillomavirus
JPH07506374A (ja) * 1992-05-01 1995-07-13 フォーシス デンタル インファーマリー フォー チルドレン う蝕予防用合成ペプチドワクチン
AUPM358894A0 (en) 1994-01-31 1994-02-24 Csl Limited Modified papilloma virus l2 protein and vlps formed therefrom
AU683564B2 (en) * 1994-05-17 1997-11-13 University Of Queensland, The Recombinant papilloma virus L1
AUPM566794A0 (en) 1994-05-17 1994-06-09 University Of Queensland, The Process and product
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
AUPN015794A0 (en) 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
CA2170839A1 (en) * 1995-03-01 1996-09-02 Janet Macinnes Bacterial preparations, method for producing same, and their use as vaccines
AUPN443995A0 (en) 1995-07-27 1995-08-17 Csl Limited Papillomavirus polyprotein
AU699547B2 (en) * 1995-07-27 1998-12-03 Csl Limited Papillomavirus polyprotein constructs
US7659119B2 (en) 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
AU5111298A (en) * 1996-11-29 1998-06-22 University Of Queensland, The Novel promiscuous t helper cell epitopes
AUPO390396A0 (en) 1996-11-29 1996-12-19 Csl Limited Novel promiscuous T helper cell epitopes
US6319503B1 (en) 1998-02-19 2001-11-20 Proteinix Company Heat shock fusion-based vaccine system
JP4434479B2 (ja) 1997-07-09 2010-03-17 ザ・ユニバーシティ・オブ・クイーンズランド 標的の細胞および組織においてタンパク質を選択的に発現するための核酸配列および方法
AU747522B2 (en) * 1997-07-09 2002-05-16 University Of Queensland, The Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue
AUPP807899A0 (en) 1999-01-08 1999-02-04 University Of Queensland, The Codon utilization
ATE231917T1 (de) 1997-08-05 2003-02-15 Stressgen Biotechnologies Corp Immunresponse gegen hpv antigene erregt von zusammensetzungen die ein hpv antigen und ein stressprotein enthalten oder einen expressionsvektor fähig zur expression dieser proteine
WO1999042564A2 (en) 1998-02-20 1999-08-26 The Rockefeller University Apoptotic cell-mediated antigen presentation to dendritic cells
US6004815A (en) 1998-08-13 1999-12-21 The Regents Of The University Of California Bacteria expressing nonsecreted cytolysin as intracellular microbial delivery vehicles to eukaryotic cells
AUPP765398A0 (en) 1998-12-11 1999-01-14 University Of Queensland, The Treatment of papillomavirus infections
AU762114B2 (en) * 1998-12-11 2003-06-19 University Of Queensland, The Treatment of papillomavirus infections

Also Published As

Publication number Publication date
CA2444048C (en) 2016-06-21
US8858951B2 (en) 2014-10-14
EP1390074B1 (en) 2017-06-07
US9993542B2 (en) 2018-06-12
ES2634256T3 (es) 2017-09-27
WO2002083181A1 (en) 2002-10-24
AUPR446801A0 (en) 2001-05-17
DK1390074T3 (en) 2017-09-25
AU2002248978B2 (en) 2008-04-17
US20150132325A1 (en) 2015-05-14
US20040241177A1 (en) 2004-12-02
EP1390074A1 (en) 2004-02-25
CA2444048A1 (en) 2002-10-24
EP1390074A4 (en) 2007-03-14

Similar Documents

Publication Publication Date Title
EP1463742A4 (en) NEW PYRAZOLO AND PYRROLO PYRIMIDINES AND THEIR USES
AU2002357119A8 (en) Mitocidal compositions and methods
EP1408978A4 (en) NOVEL PHENYLAMINO-PYRIMIDINES AND THEIR USE
PL367134A1 (en) Novel composition
AU2002357748A8 (en) Osteopontin-related compositions and methods
GB0114069D0 (en) Composition
GB0107651D0 (en) Composition
GB0122113D0 (en) Composition
PT1390074T (pt) Novas composições e suas utilizações
EP1408985A4 (en) NEW PYRIDOPYRIMIDONE AND ITS USES
EP1364646A4 (en) FENOFIBRATE CONTAINING COMPOSITION
GB0115679D0 (en) Composition
GB0117305D0 (en) Composition
GB0126081D0 (en) Composition
AU2002359869A8 (en) Pak5-related compositions and methods
GB0121454D0 (en) Composition
GB0126085D0 (en) Composition
GB0124023D0 (en) Novel compositions and use
GB0119353D0 (en) Novel composition and use
GB0122906D0 (en) Compounds and compositions
GB0119468D0 (en) Novel composition
GB0119470D0 (en) Novel composition
GB0100458D0 (en) Novel composition
GB0118976D0 (en) Composition
GB0118516D0 (en) Composition